-->

Company Registry

Biostage Inc (AKA:Harvard Apparatus Regenerative Technology~HART~Harvard Bioscience Inc ~ HBIO )
Profile last edited on: 1/12/2022

Next-generation esophageal implants for patients battling life-threatening conditions
Year Founded
2012
First SBIR Year
2018
Latest SBIR Award
2020
Program Status
Active

WikiProfile

Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

84 October Hill Road Suite 11
Holliston, MA 01746
   (774) 233-7300
   N/A
   www.biostage.com
Multiple Locations:   
Congressional District:   05
County:   Middlesex

Public Profile

Originally dba Harvard Apparatus Regenerative Technology, Inc. (Nasdaq: HART), in March 2016, the firm changed its name to Biostage, Inc. and subsequently shifted to trading on OTC (OTC: BSTG). Working in the space of regenerative medicine, patient-specific stem cell therapy, and tissue engineering, the company develops customized bioengineered organ implants designed to restore organ function of the esophagus, trachea and bronchus damaged by disease or trauma. Biostage's bioengineered organ implants are based on the firm's Cellframe technology comprise of a biocompatible scaffold that is seeded with the recipient's own stem cells dedicated internal team of materials scientists, engineers and biologists, working with external collaborators, is addressing the life-threatening conditions of congential defects, trauma and cancers of the esophagus, bronchi and trachea. Even when they are available, current treatment can drastically and adversely impact quality of life while also having a significant mortality and morbidity rate. Biostage is developing radically new ways to treat these life-threatening conditions with clinical trials being designed to offer the potential of improved mortality rates, reduced complications, and enhanced patient quality of life.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
10-14
Revenue Range
1M-1.5M
VC funded?
Yes
Public/Private
Publicly Traded
Stock Info
OTC : BSTG
IP Holdings
5-9

Awards Distribution by Agency

Most Recent SBIR Projects

Key People / Management

  David T Green -- Founder and now CEO

  James J McGorry -- CEO & President

  Hong Yu -- President

  Ginger A Abraham-Freel -- Director of Quality & Operations

  Jeff Bouchard -- Director of Engineering, Manufacturing and Quality

  Peter M Chakoutis -- VP of Finance

  William Fodor -- Chief Scientific Officer

  Shunfu Hu -- VP of Business Development & Operations

  Linghui Meng -- Director of Product Development

  Tina Roffidal -- Director of Clinical and Pre-Clinical Development

  Sumati Sundaram -- Director of Cell Biology

SBIR firms in the news

There are no news available.